Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T04977
(Former ID: TTDI01684)
|
|||||
| Target Name |
Oxalate absorption (Oxalate absor)
|
|||||
| Gene Name |
NO-GeName
|
|||||
| Target Type |
Clinical trial target
|
[1] | ||||
| Disease | [+] 1 Target-related Diseases | + | ||||
| 1 | Inborn carbohydrate metabolism error [ICD-11: 5C51] | |||||
| UniProt ID | ||||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Clinical Trial Drug(s) | [+] 1 Clinical Trial Drugs | + | ||||
| 1 | Reloxaliase | Drug Info | Phase 3 | Hyperoxaluria | [2] | |
| Discontinued Drug(s) | [+] 1 Discontinued Drugs | + | ||||
| 1 | ALTU-237 | Drug Info | Discontinued in Phase 1 | Hyperoxaluria | [3] | |
| Mode of Action | [+] 2 Modes of Action | + | ||||
| Replacement | [+] 1 Replacement drugs | + | ||||
| 1 | Reloxaliase | Drug Info | [4] | |||
| Modulator | [+] 1 Modulator drugs | + | ||||
| 1 | ALTU-237 | Drug Info | [1] | |||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Hyperoxaluria: a gut-kidney axis. Kidney Int. 2011 Dec;80(11):1146-58. | |||||
| REF 2 | ClinicalTrials.gov (NCT03847090) Establishing the Safety and Efficacy of Reloxaliase in Patients With Enteric Hyperoxaluria (URIROX-2). U.S. National Institutes of Health. | |||||
| REF 3 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020198) | |||||
| REF 4 | Clinical pipeline report, company report or official report of Allena Pharmaceuticals. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.